Board of Trustees


  • Steven E. Wallach, Esq.


  • Carol G. Kelly


  • Shelby K. Schultz



  • Karen H. Antman, M.D.

    Trustee Emerita

    Provost of the Medical Campus and Dean, Boston University School of Medicine, John Sanson Professor of Health Sciences 


  • Genevieve Boland, M.D., Ph.D., FACS

    Director, Melanoma Surgery Program,
    Massachusetts General Hospital
    Assistant Professor, Harvard Medical School
    Associate Member, Broad Institute of MIT and Harvard

  • Michael J. Droller, M.D.

    Katherine and Clifford Goldsmith Professor of Urology, Professor of Oncology, Chairman Emeritus Department of Urology, The Mt. Sinai Medical Center


  • Douglas V. Faller, Ph.D., M.D

    Karin Grunebaum Professor in Cancer Research, Emeritus,
    Boston University School of Medicine

  • Michael A. Gimbrone, Jr., M.D.

    Elsie T. Friedman Professor of Pathology, Harvard Medical School; Director, Center for Excellence in Vascular Biology, Chairman Emeritus, Department of Pathology, Brigham and Women's Hospital

  • David E. Golan, M.D., Ph.D.

    Harvard Medical School Dean for Basic Science and Graduate Education and Special Advisor for Global Programs;
    Professor of Biological Chemistry and Molecular Pharmacology;
    George R. Minot Professor of Medicine;
    Senior Physician, Brigham and Women's Hospital and Dana-Farber Cancer Institute

  • Yvonne F. Grunebaum

  • Edward Harlow, Jr., Ph.D.

    Virginia and D.K. Ludwig Professor of Cancer Research and Teaching, Harvard Medical School; Senior Advisor to the Director, National Cancer Institute.

  • Robyn Karnauskas, Ph.D.

    Director, Biotechnology Analyst, Citigroup

  • Christopher F. Kelly

  • Adam Lerner, M.D.

    Professor, Departments of Medicine and Pathology, Boston University School of Medicine

  • Shawna B. Wallach

Karin Grunebaum

Karin Grunebaum (née Wassermann) was born in Berlin, Germany on September 2, 1918 – the second daughter of a prominent banker. Her apparently very beautiful and loving mother died of an unspecified illness when Karin was only 6 years old – which would prove to be a strange precursor to Karin’s own life.

In June 1958, at age 39, Karin Grunebaum, the mother of 4 and a loving wife, suddenly passed away from cancer only three months after giving birth to her youngest child. Because her pregnancy had masked the symptoms of cancer, the disease had already metastasized throughout her entire body by the time the cancer was diagnosed a month after giving birth. There was no way to know what type of cancer she had. The primary site of the malignancy remained unknown.

After Karin passed away, her husband, Fritz Grunebaum, established the Karin Grunebaum Cancer Research Foundation as a lasting memory to his beloved wife so that other families could avoid such a tragedy by helping to identify and treat all tumors regardless of location.

Learn more...

The Foundation's Mission and its chosen path to Mission Accomplishment:

Because Karin Grunebaum died at age 39 from an unknown primary site malignancy, the overriding objective of the Karin Grunebaum Cancer Research Foundation is the eradication of all types of cancer. The Foundation's original Declaration of Trust, written in 1958, mandates that the Foundation's funds be exclusively used for "...aiding research in and study of the cause, treatment and cure of cancer."

The Foundation's Trustees firmly believe that the eradication of cancer will only occur through successful research accomplishments which are followed by successful practical/commercial application. Thus, the Foundation has chosen to invest its funds directly in dedicated cancer researchers in hope of helping them achieve significant accomplishments to eliminate all types of carcinomas and thereby eradicate each and every type of cancer.

Focus On Research

The Foundation is very proud of the success achieved by our Fellows who have been working and teaching at some of the most prestigious and front-line cancer research facilities in the world, including: Adaptive Biotechnologies, AMGEN Corp, City of Hope, Dana-Farber Cancer Institute, Duke Health, Immune Design, Johns Hopkins,  Massachusetts General Hospital, M.D. Anderson Cancer Center, Memorial Sloan Kettering Cancer Center, Merck & Co., Mersana Therapeutics, Mount Sinai School of Medicine, NYU Langone Medical Center, Siteman Cancer Center, SLJ Consulting, Stanford University Cancer Center, UC Irvine Health, UCLA Medical Center, University of California (San Francisco), University of Maryland School of Medicine, University of Pennsylvania School of Medicine, University ot Texas Health Science Center, University of Vermont Medical School, Vanderbilt University Medical Center, Weill Cornell Medical Center, Yale Cancer Center and Zyngenia Corporation, in addition to our sponsored institutions of Harvard Medical School and Boston University School of Medicine.

Learn more...

Donations Accepted

The support we are able to give to the dedicated cancer researchers is solely dependent on donations from you -- we have no other funding. Find out how you can make a tax-deductible contribution online or via mail on our Support and Contributions for the Grunebaum Foundation section

Learn more...

Benefits of Giving

Whether you want to eliminate taxes or benefit from an increased income stream, there is a gift to fit every objective. Please review our Benefits of Giving to charitable organizations to learn how you can give as well as receive.

Learn more...

Meetings & Events

The following is a list of planned meetings.

There are no events or meetings planned at this time

Review a full list of KGCRF events...

About the Institutions We Support

If you are interested in the institutions our Fellows attend you can review the Universities our KGCRF Fellows attend here.

Learn more...

Fellowship Application

Fellowships are available to junior faculty members at Harvard Medical School and the Boston University School of Medicine. If you are interested in applying to become a Karin Grunebaum Fellow, please use the following links to the three institutions.

Boston University
Harvard Medical School

Our Current Fellows

(and Research Updates)

  • Maria Dafne Cardamone

    Ph.D., Research Assistant Professor of Biochemistry, Boston University School of Medicine

    Research Information from Maria Dafne Cardamone will be coming soon.

  • Russell Jenkins

    M.D., Ph.D., Instructor in Medicine, Harvard Medical School

    TBK1 As A Novel Target to Reprogram the Tumor Immune Microenvironment

  • Karin Grunebaum Chair at Boston University

    The Karin Grunebaum Chair in Cancer Research was established in 2002 at the Boston University School of Medicine. In April 2019, Boston University's Board of Trustees approved Professor Julie Palmer, Sc.D. as the second Karin Grunebaum Professor in Cancer Research. In addition, Dr. Palmer serves on the Foundation's Board of Trustees.

    This professorship represents the first in the field of Cancer Research at the Boston University School of Medicine.